Successful Treatment of Refractory Cutaneous Protothecosis With MAT2203, an Oral Lipid Nanocrystal Formulation of Amphotericin B

Abstract Prototheca wickerhamii is a rare cause of cutaneous and systemic infection that requires long treatment courses with potentially toxic medications. We describe a patient with cutaneous protothecosis refractory to triazole monotherapy who experienced clinical and radiographic improvement wit...

Full description

Saved in:
Bibliographic Details
Published inOpen forum infectious diseases Vol. 11; no. 8; p. ofae428
Main Authors Pechacek, Joseph, Schmitt, Monica M, Ferrè, Elise M N, Webb, Taura, Goldberg, Joel, Pathan, Sabina, Banerjee, Camellia, Barber, Princess, DiMaggio, Thomas, Quinn, Anne, Matkovits, Theresa, Castelo-Soccio, Leslie, Nussenblatt, Veronique, Lionakis, Michail S
Format Journal Article
LanguageEnglish
Published US Oxford University Press 01.08.2024
Subjects
Novel ID Cases
cutaneous infection
amphotericin
MAT2203
novel antifungals
Online AccessGet full text

Cover

More Information
Summary:Abstract Prototheca wickerhamii is a rare cause of cutaneous and systemic infection that requires long treatment courses with potentially toxic medications. We describe a patient with cutaneous protothecosis refractory to triazole monotherapy who experienced clinical and radiographic improvement with the novel oral lipid nanocrystal formulation of amphotericin B without experiencing toxicity.
Bibliography:ObjectType-Case Study-2
SourceType-Scholarly Journals-1
ObjectType-Feature-4
content type line 23
ObjectType-Report-1
ObjectType-Article-3
Potential conflicts of interest. T.M. is an employee of Matinas Biopharma and has an equity interest and receives support for attending meetings and/or travel and reports a role as board director for Apilli Therapeutics and GoodCap Pharmaceuticals. All other authors report no potential conflicts.
ISSN:2328-8957
2328-8957
DOI:10.1093/ofid/ofae428